Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07196748 · ClinicalTrials.gov registry record · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 3 study of Colitis, Ulcerative, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 882
- Enrollment target
- 20
- Study locations
NCT07196748 is a Phase 3 study of Colitis, Ulcerative that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 882 participants, above the 374-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (136% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT07196748, a Phase 3 study of Colitis, Ulcerative, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 882 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops tiny open ulcers).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Icotrokinra
Study Locations (20)
California
- Clinnova Research - Anaheim
- Southern California Research Center - Coronado
- Om Research LLC - Lancaster
- TLC Clinical Research Inc - Los Angeles
- GastroIntestinal Bioscience - Los Angeles
- Om Research LLC - Oxnard
- Clinical Applications Laboratories, Inc - San Diego
- Medical Associates Research Group, Inc. - San Diego
Florida
- American Institute of Research - Cutler Bay
- Nature Coast Clinical Research - Inverness
- Florida Research Institute - Lakewood Rch
- GCP Clinical Research - Tampa
Georgia
- Atlanta Gastroenterology Associates - Atlanta
- Children's Center for Digestive Health Care - Atlanta
- Gastroenterolgy Associates of Central GA - Macon
Connecticut
- Nuvance Health Danbury Hospital - Danbury
- Connecticut Children's Medical Center - Hartford
Arizona
- AZ Gastro Care - Chandler
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Kansas
- Cotton O'Neil Digestive Health Center - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 882 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2032-01-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07196748
The ClinicalTrials.gov registry entry for NCT07196748 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 882 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 374-participant average among 28 other Colitis, Ulcerative trials with a reported enrollment target (136% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colitis, Ulcerative appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07196748 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07196748 about?
NCT07196748 is a clinical study titled "A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis". The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the col...
What is the current status of trial NCT07196748?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 882 participants. The study started on 2025-10-01. Estimated completion is 2032-01-13.
What conditions does trial NCT07196748 study?
This clinical trial studies the following conditions: Colitis, Ulcerative.
What interventions are being tested in trial NCT07196748?
The interventions under investigation include: Placebo (DRUG), Icotrokinra (DRUG).
Who is sponsoring clinical trial NCT07196748?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07196748 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colitis, Ulcerative
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.